Collaboration and License Agreements - Pfizer Collaboration and License Agreement (Details) - USD ($)		1 Months Ended	9 Months Ended	12 Months Ended
	Dec. 26, 2020	Dec. 31, 2020	Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2022	Jul. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds received from license agreement milestone	$ 146,400,000		$ 0
Amounts due to Pfizer			25,768,000	$ 25,768,000		$ 32,563,000
Pfizer
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of revenue recognized	100.00%
Upfront payment received		$ 650,000,000
Proceeds received from license agreement milestone	$ 150,000,000		100,000,000
Maximum payment from milestones achieved	3,800,000,000
Maximum payment from regulatory milestones achieved	100,000,000						$ 100,000,000
Maximum aggregate payment from milestones achieved	200,000,000
Maximum payment from sales-related milestones achieved	$ 3,500,000,000
Costs covered by company				50,000,000	$ 100,000,000
Repayment period	2 years
Reduction in cost share advance from implied financing costs	$ 3,600,000
Deferred revenue, recognition period	6 years
Amounts due to Pfizer			25,800,000	25,800,000		32,600,000
Amounts due to collaboration partner, share of profits			$ 26,800,000	$ 26,800,000		$ 14,100,000
Percentage of revenue recognized by counterparty			50.00%	50.00%		50.00%
Amounts due to collaboration partner, reimbursement of allowable expenses			$ 1,000,000	$ 1,000,000		$ 18,500,000
Reimbursement of allowable expenses (as a percent)			50.00%	50.00%		50.00%
Reimbursement of total expenses (as a percent)			100.00%	100.00%